EUVIMEDEUVIMED entdecken
Crossref

Targeting lung tissue resident immunity via intramuscular vaccination for protection against Mycobacterium tuberculosis 2300551

Meghan Mouton, Rebecca Horowitz, Vanessa Limbert, Louay Bachnak, Lisa Morici, Charlotte Hankin, James McLachlan

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.1214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Meghan Mouton und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

An improved tuberculosis (Tb) vaccine is needed to confer long lasting protection for all individuals targeting correlates of protection (CoP). We seek to generate a parenterally administered vaccine that induces strong lung-resident immune responses to protect against Mtb.

Methods

We hypothesize that intramuscular (IM) vaccination with adjuvant double mutant Escherichia coli heat-labile toxin (dmLT) and a bacterial OMV-derived adjuvant (T-vant) will induce a robust response, driving tissue resident immunity in the lung. Mice will be vaccinated IM with antigen alone or antigen with the cocktail in a prime-boost fashion. Two weeks post boost, mice will be intravenously injected with CD45 antibody to differentiate circulating vs non-circulating tissue resident cells. Lymph nodes, spleens, and lungs will be stained with antigen-specific MHCII tetramer to identify CD4+ T cells that are vaccine-specific. Flow cytometry will identify cells that are tissue resident (IV CD45-CD69+P2X7R+), and serum and BAL fluid will be collected for antibody titers.

Results

In comparison to other routes, IM vaccination generated the highest number of vaccine specific CD4+ and CD8+ T cells. Following IM immunization, we observed significantly higher numbers of tissue resident vaccine-specific CD4+ in the lung of adjuvant vaccinated mice than naïve or antigen alone groups. These cells preferentially displayed a TH1/TH17 phenotype, which are key correlates of protection for Mtb infection.

Conclusion

These findings suggest that our combination adjuvanted vaccine might produces lung-resident immune responses that could provide increased protection against lung infections. We hope to utilize this in developing novel vaccines for Tb that target CoPs for lasting protection for all individuals. Funding Source NIH Topic Categories Mucosal and Regional Immunology (MUC)

Zitieren

APA

Mouton, M., Horowitz, R., Limbert, V., Bachnak, L., Morici, L., Hankin, C., & McLachlan, J. (2026). Targeting lung tissue resident immunity via intramuscular vaccination for protection against Mycobacterium tuberculosis 2300551. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1214

Vancouver

Mouton M, Horowitz R, Limbert V, Bachnak L, Morici L, Hankin C, et al. Targeting lung tissue resident immunity via intramuscular vaccination for protection against Mycobacterium tuberculosis 2300551. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1214

BibTeX
@article{Mouton2026,
  author = {Mouton, Meghan and Horowitz, Rebecca and Limbert, Vanessa and Bachnak, Louay and Morici, Lisa and Hankin, Charlotte and McLachlan, James},
  title = {Targeting lung tissue resident immunity via intramuscular vaccination for protection against Mycobacterium tuberculosis 2300551},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.1214}
}
Kostenlos starten →